EMA Authorised: Nucala (Mepolizumab) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

EMA has authorised Nucala (mepolizumab) for asthma, confirming regulatory approval in the European Union.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Nucala (mepolizumab)

Snippet

Status: Authorised. Therapeutic area: Asthma. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 21/07/2026